Literature DB >> 11679562

OXA-35 is an OXA-10-related beta-lactamase from Pseudomonas aeruginosa.

D Aubert1, L Poirel, A B Ali, F W Goldstein, P Nordmann.   

Abstract

Pseudomonas aeruginosa clinical isolate PA35 is resistant to amino- and ureido-penicillins, has intermediate susceptibility to cefsulodin, cefepime and aztreonam, and is susceptible to imipenem and ceftazidime. Cloning and sequencing revealed a new beta-lactamase variant, OXA-35, sharing 96% amino acid identity with OXA-10. OXA-35 displays a restricted-substrate hydrolysis profile with improved hydrolysis of amoxicillin and cloxacillin compared with OXA-10. OXA-35 differs from derivatives OXA-19 and OXA-28 by one amino acid substitution and may be a progenitor of these OXA-13-like extended-spectrum beta-lactamases.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11679562     DOI: 10.1093/jac/48.5.717

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  12 in total

1.  Characterization of the First OXA-10 Natural Variant with Increased Carbapenemase Activity.

Authors:  Stathis D Kotsakis; Carl-Fredrik Flach; Mohammad Razavi; D G Joakim Larsson
Journal:  Antimicrob Agents Chemother       Date:  2018-12-21       Impact factor: 5.191

2.  Involvement of the MexXY-OprM efflux system in emergence of cefepime resistance in clinical strains of Pseudomonas aeruginosa.

Authors:  Didier Hocquet; Patrice Nordmann; Farid El Garch; Ludovic Cabanne; Patrick Plésiat
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

3.  Breaking antimicrobial resistance by disrupting extracytoplasmic protein folding.

Authors:  R Christopher D Furniss; Nikol Kaderabkova; Declan Barker; Patricia Bernal; Evgenia Maslova; Amanda A A Antwi; Helen E McNeil; Hannah L Pugh; Laurent Dortet; Jessica M A Blair; Gerald Larrouy-Maumus; Ronan R McCarthy; Diego Gonzalez; Despoina A I Mavridou
Journal:  Elife       Date:  2022-01-13       Impact factor: 8.713

4.  OXA-143, a novel carbapenem-hydrolyzing class D beta-lactamase in Acinetobacter baumannii.

Authors:  Paul G Higgins; Laurent Poirel; Marlene Lehmann; Patrice Nordmann; Harald Seifert
Journal:  Antimicrob Agents Chemother       Date:  2009-09-21       Impact factor: 5.191

5.  Class D β-lactamases: are they all carbapenemases?

Authors:  Nuno T Antunes; Toni L Lamoureaux; Marta Toth; Nichole K Stewart; Hilary Frase; Sergei B Vakulenko
Journal:  Antimicrob Agents Chemother       Date:  2014-01-27       Impact factor: 5.191

6.  Mechanisms of Resistance to Ceftolozane/Tazobactam in Pseudomonas aeruginosa: Results of the GERPA Multicenter Study.

Authors:  Damien Fournier; Romain Carrière; Maxime Bour; Emilie Grisot; Pauline Triponney; Cédric Muller; Jérôme Lemoine; Katy Jeannot; Patrick Plésiat
Journal:  Antimicrob Agents Chemother       Date:  2021-01-20       Impact factor: 5.191

7.  Molecular characterization of a new class 3 integron in Klebsiella pneumoniae.

Authors:  Mário Correia; Filipa Boavida; Filipa Grosso; M J Salgado; L M Lito; J Melo Cristino; Sónia Mendo; Aida Duarte
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

8.  Molecular analysis of metallo-beta-lactamase gene bla(SPM-1)-surrounding sequences from disseminated Pseudomonas aeruginosa isolates in Recife, Brazil.

Authors:  Laurent Poirel; Marcelo Magalhaes; Miguel Lopes; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

Review 9.  Diversity, epidemiology, and genetics of class D beta-lactamases.

Authors:  Laurent Poirel; Thierry Naas; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2009-08-31       Impact factor: 5.191

10.  Phenotypic/Genotypic Profile of OXA-10-Like-Harboring, Carbapenem-Resistant Pseudomonas aeruginosa: Using Validated Pharmacokinetic/Pharmacodynamic In Vivo Models To Further Evaluate Enzyme Functionality and Clinical Implications.

Authors:  Christian M Gill; Adrian Brink; Chun Yat Chu; Jennifer Coetzee; George Dimopoulos; Clinton Moodley; Christoffel Johannes Opperman; Spyros Pournaras; Fred C Tenover; Isabella A Tickler; Hafsah Deepa Tootla; Sophia Vourli; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2021-07-26       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.